Roivant Sciences (ROIV) Research & Development (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Research & Development came in at $482.9 million in Q4 2025, up 19.17% YoY from $405.2 million in Q4 2024, and up 193.41% on a QoQ basis from $164.6 million in Q3 2025.
Roivant Sciences (ROIV) Research & Development (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Research & Development data on file, last reported at $482.9 million in Q4 2025.
- Quarterly Research & Development rose 19.17% year-over-year to $482.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 billion (up 20.42% YoY) and the FY2026 annual result came in at $681.8 million, up 23.87% from the prior year.
- Research & Development improved to $482.9 million in Q4 2025, from $164.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $482.9 million in Q4 2025 to a low of $78.5 million in Q2 2021.
- A 5-year average of $217.4 million and a median of $143.1 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 73.0% — and 2023, when it decreased 15.51%.
- Tracing ROIV's Research & Development over 5 years: stood at $348.0 million in 2021, then climbed by 13.05% to $393.4 million in 2022, then fell by 15.51% to $332.4 million in 2023, then climbed by 21.91% to $405.2 million in 2024, then rose by 19.17% to $482.9 million in 2025.
- The last three Research & Development figures came in at $482.9 million (Q4 2025), $164.6 million (Q3 2025), and $152.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 202.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 202.02 Mn |
| Dec 31, 2025 | 482.87 Mn |
| Sep 30, 2025 | 164.57 Mn |
| Jun 30, 2025 | 152.92 Mn |
| Dec 31, 2024 | 405.18 Mn |
| Sep 30, 2024 | 143.07 Mn |
| Jun 30, 2024 | 120.51 Mn |
| Dec 31, 2023 | 332.35 Mn |
| Sep 30, 2023 | 114.79 Mn |
| Jun 30, 2023 | 125.13 Mn |
| Dec 31, 2022 | 393.36 Mn |
| Sep 30, 2022 | 132.00 Mn |
| Jun 30, 2022 | 135.83 Mn |
| Dec 31, 2021 | 347.96 Mn |
| Sep 30, 2021 | 132.10 Mn |
| Jun 30, 2021 | 78.52 Mn |
| Dec 31, 2020 | 202.26 Mn |
| Sep 30, 2020 | 97.41 Mn |
| Jun 30, 2020 | 58.73 Mn |